Law360, New York (August 18, 2009) -- The U.S. Patent and Trademark Office has granted generic-drug maker Apotex Corp.'s request for re-examination of Sanofi-Aventis' patent for blood-thinner Plavix, as Apotex fights to break down intellectual property barriers to its attempt to market a generic version of the blockbuster drug.
France-based Sanofi-Aventis and New York-based Bristol-Myers Squibb Co., which co-market Plavix, confirmed Tuesday that they had received notice from the patent agency that it would be taking a new look...
